Recently, Ladder Med successfully completed its Series B+ financing, raising an amount of several hundred million CNY.
Founded in August 2021, Ladder Med specializes in the research, development, and application of minimally invasive implantable Brain-Computer Interface (BCI) technology. Recently, Ladder Med announced the successful completion of its second invasive BCI clinical trial. This trial achieved a significant technical breakthrough, marking a leap from 2D screen cursor control to 3D physical world interaction. It enabled a patient with high-level paraplegia to stably control a power wheelchair and a robotic dog using brain signals, achieving autonomous mobility and object retrieval in real-life scenarios.
Ladder Med aims to accelerate the clinical transformation and application verification of its new products, bringing BCI technology into practical clinical use. With an open mind, the company seeks to collaborate with various smart devices and application platforms to jointly promote the high-quality development of China's BCI technology.
As the legal counsel for Ladder Med, Llinks leverage its extensive project experience in the investment and financing sector, has provided professional legal services for Ladder Med across multiple rounds of financing.
Llinks Engagement Team
Selena She, Partner
Colin Shi, Partner
Chunhui Bai, Associate
Xuewei Yu, Associate
